IperionX validated its GenX™ continuous titanium production platform at its Virginia R&D facility through four campaigns totaling over 500 kg of powder. The system achieved six times the throughput and reduced power consumption by more than 75% compared to batch processing, while lowering magnesium and hydrogen use by over 45% and 60%, respectively. All spherical samples met ASTM Grade 23 oxygen specifications, with angular samples meeting Grade 5 standards. The company plans to optimize operations in Q4 2026 and begin engineering evaluations for the first industrial-scale GenX™ line. IperionX operates in the critical materials industry, producing high-performance titanium alloys using patented low-energy technologies.

IperionX Limited announced that the U.S. Army awarded Task Order 2 under its existing US$99 million SBIR Phase III contract for Low-Cost, Domestic Titanium for Defense Applications. The task order has a base value of US$18.5 million, with US$11.5 million currently funded and obligated to cover three priority industrialization work packages and an initial allotment to a fourth. Unexercised options could increase the total potential value to US$25.4 million. Funding supports equipment for continuous HSPT™ processing and in-house titanium fastener finishing at IperionX’s Virginia facility, aiming to expand domestic powder-to-part manufacturing capacity for defense applications such as track pins and bolts. The period of performance is from August 28, 2026, to August 27, 2030. IperionX Limited operates in the advanced materials and mining industry, utilizing patented technologies to produce titanium metals and critical minerals.

IperionX Limited announced a proposed redomiciliation to Texas and the appointment of Michael J. Loparco as an independent non-executive director effective August 3, 2026. The company intends to establish a Texas-incorporated parent company to align its legal structure with its U.S.-based operations in Tennessee, Virginia, and Utah, replacing its existing ADS listing on Nasdaq with direct common stock. This strategic move aims to simplify the investment framework for U.S. investors and enhance access to capital markets while maintaining underlying assets and operational priorities. Loparco brings extensive experience from Symbotic Inc. and Jabil Inc., strengthening the board's capabilities for industrial scale-up. IperionX operates in the critical minerals and advanced manufacturing industry, producing titanium metal and alloys using patented technologies.

IperionX Limited priced an underwritten U.S. public offering of 2,275,000 ADSs at US$21.98 per ADS on July 7, 2026, generating approximately US$50 million in gross proceeds to fund titanium manufacturing scale-up and the Atlas-Titan critical minerals project. The company also completed the acquisition of adjacent Atlas assets for US$3 million on July 1, 2026, adding high-grade stockpiles and infrastructure to its Titan Definitive Feasibility Study platform. During the quarter ended June 30, 2026, IperionX held US$35.2 million in cash and received a US$2.4 million reimbursement under the DPA Title III program immediately after quarter-end. Operations continued on a 24/7 schedule with temporary furnace downtime resolved without impacting downstream supply, while the company targets a 200 tpa production run-rate by end of 2026. IperionX operates in the critical minerals and titanium metal manufacturing industry, producing domestic titanium powder and components for defense, aerospace, and industrial applications.

IperionX Limited entered into an Underwriting Agreement with Cantor Fitzgerald & Co. on July 7, 2026, and filed a corresponding legal opinion from Thomsons on July 9, 2026. These documents are incorporated by reference into the company's existing Registration Statements on Form F-3 and Form S-8. The company operates in the materials industry, focusing on the production of high-purity silicon and related technologies.